checkAd

    EQS-Adhoc  253  0 Kommentare Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued

    Für Sie zusammengefasst
    • Phase III trials of xevinapant in head & neck cancer discontinued.
    • Decision based on interim analysis not meeting primary objective.
    • Xevinapant still under investigation, not approved worldwide.

    EQS-Ad-hoc: Merck KGaA / Key word(s): Study results
    Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued

    24-Jun-2024 / 19:00 CET/CEST
    Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.


    Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Merck KGaA!
    Long
    144,07€
    Basispreis
    1,09
    Ask
    × 14,11
    Hebel
    Short
    164,24€
    Basispreis
    1,09
    Ask
    × 14,11
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued

    Darmstadt, June 24, 2024: Merck KGaA is investigating a treatment of xevinapant plus platinum-based chemotherapy (CRT), compared to placebo plus CRT, in patients with unresected locally advanced head and neck cancer in a phase III clinical trial (TrilynX). The company decided to discontinue this study. The decision follows a pre-planned interim analysis performed by the study’s Independent Data Monitoring Committee, which found that the trial would be unlikely to meet its primary objective of prolonging event-free survival. Given the totality of the data, the company decided to also stop the phase III clinical trial X-Ray Vision (xevinapant plus radiotherapy, compared to placebo plus radiotherapy in patients who underwent resection of locally advanced head and neck cancer).

     

    Xevinapant is currently under clinical investigation and not approved for any indication anywhere in the world.

    Esther Döringer
    Merck KGaA
    Frankfurter Straße 250
    64293 Darmstadt
    Germany
    Phone: +49 151 1454 7809
    Email: esther.doeringer@merckgroup.com
    Internet: https://www.merckgroup.com/en
    ISIN: DE0006599905
    WKN: 659990
    Indices: DAX

    Stock exchanges: Regulated Market of Frankfurt am Main (Prime Standard); Open Markets of Berlin, Düsseldorf, Hamburg, Hanover, Munich, Stuttgart; EUREX derivatives exchange; London, SIX




    Contact:
    Esther Döringer, Head of Media Relations

    End of Inside Information

    24-Jun-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.eqs-news.com


    Language: English
    Company: Merck KGaA
    Frankfurter Str. 250
    64293 Darmstadt
    Germany
    Phone: +49 (0)6151 72 - 2702
    E-mail: Friederike.Segeberg@merckgroup.com
    Internet: https://www.merckgroup.com/de
    ISIN: DE0006599905
    WKN: 659990
    Indices: DAX
    Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, SIX
    EQS News ID: 1931843

     
    End of Announcement EQS News Service

    1931843  24-Jun-2024 CET/CEST

    fncls.ssp?fn=show_t_gif&application_id=1931843&application_name=news&site_id=wallstreet~~~257e03b8-9cbc-48b8-b6a5-ec526abf7b8e

    Merck

    +0,36 %
    -0,93 %
    -12,83 %
    -2,80 %
    +1,81 %
    -11,96 %
    +61,01 %
    +133,25 %
    +599,89 %
    ISIN:DE0006599905WKN:659990


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-Adhoc Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued EQS-Ad-hoc: Merck KGaA / Key word(s): Study results Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued 24-Jun-2024 / 19:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the …

    Schreibe Deinen Kommentar

    Disclaimer